| RESEARCH ARTICLE
|Year : 2018 | Volume
| Issue : 4 | Page : 192-196
Cutaneous adverse drug reactions with fixed-dose combinations: Special reference to self-medication and preventability
Ratikanta Tripathy1, Kali Prasad Pattnaik2, Suhasini Dehury3, Sibasis Patro4, Prasanjeet Mohanty3, Swayam Sourav Sahoo2, Srikanta Mohanty3
1 Department of Pharmacology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
2 ADR Monitoring Centre, Department of Pharmacology, Cuttack, Odisha, India
3 Department of Pharmacology and Dermatology, SCB Medical College, Cuttack, Odisha, India
4 Department of Dermatology, MKCG Medical College, Berhampur, Odisha, India
OBJECTIVES: To identify the association of cutaneous adverse drug reactions (CADRs) with use of fixed-dose combinations (FDCs) and to compare the occurrence of preventable CADRs between self-medication and prescribed medication of FDCs.
PATIENTS AND METHODS: All cases of suspected CADRs with the use of FDCs were collected, and causality assessment was carried out using the WHO UMC scale. The burden of CADRs on self-medication and prescribed medication was found out. Preventability status was analyzed by Schumock and Thornton Criteria and compared between self-medication and prescribed medication.
RESULTS: A total of 74 CADRs were detected; 68.91% were detected with antimicrobial and 31.09% with nonsteroidal anti-inflammatory drug-based FDCs. Fluoroquinolones + nitroimidazole was the most commonly suspected medications. Majority of CADRs (44.59%) were fixed-drug eruptions, which was significantly higher than others (P = 0.002). Analysis of preventability showed that there was a significantly higher occurrence of definitely preventable CADRs in self-medication group (40%) in comparison to prescribed group (6.81%), P = 0.028.
CONCLUSIONS: Self-medication with FDCs is quite common and associated with a higher rate of preventable CADRs in comparison to that in prescribed medication.
Dr. Kali Prasad Pattnaik
SCB Medical College, Cuttack, Odisha
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*